Suppr超能文献

当代感觉神经性听力损失治疗方向。

Contemporary directions in the therapy of sensory hearing loss.

机构信息

Chair and Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Warsaw, Poland.

Scientific Research Group at the Department of Otorhinolaryngology Head and Neck Surgery, Medical University of Warsaw, Poland.

出版信息

Otolaryngol Pol. 2024 Jul 25;78(4):29-38.

Abstract

<b>Introduction:</b> More than 5% of the world's population experience hearing impairment. The most common form is presbycusis (age-related hearing loss; ARHL). It affects almost one in three people over the age of 65. The hair cells of the cochlea play an important role in the process of sound registration. Genetic mutations, aging and environmental factors can cause damage that contributes to the hearing loss.<b>Methods and results:</b> The currently explored research directions include drug treatments, gene therapies, and stem cell therapies. To date, no significant differences in the therapeutic effect depending on the route of corticosteroid administration have been demonstrated in patients with moderate to severe hearing loss. New dexamethasone-containing hydrogel formulations, as well as lipid formulations, thermosensitive polymers, and nanoparticles, have been developed to achieve high drug concentrations in the inner ear structures. Otoprotective effects of antioxidants or substances that modify the toxic effects of e.g. cisplatin, are also being studied. Attempts at auditory cells' regeneration seem promising in hearing loss research. Substances that regulate the central mechanisms of the Notch and Wnt pathways are being explored to this end. The genetic determinants of presbycusis suggest that interference at the level of specific genes may be a promising option for the treatment of this condition. With the CRISPR/Cas9 technology, the functions of inner ear genes can be effectively studied by disrupting normal gene alleles. The CRISPR/Cas9 complexes developed to target specific genes are delivered using cationic lipids, proteins, and viral vectors. They are then transported through the round window membrane by diffusion, without the need to surgically disrupt the inner ear. The potential of using antisense oligonucleotides to treat hereditary deafness caused by hair cell degeneration has also been established. Another research direction is related to stem cells being used for the development of in vitro 3D models of the human inner ear. Studies are also pursued to identify the mechanisms underlying the formation of cochlear organoids from pluripotent cells as well as determine the critical time points and events for cochlear sensory epithelial development and targeted hair cell differentiation.<b>Conclusions:</b> In summary, significant progress has been made over the past decade in the search for novel therapies for sensory hearing loss. This line of research remains an ambitious and important area for further exploration.

摘要

<b>引言:</b>全球超过 5%的人口存在听力障碍。最常见的形式是老年性聋(年龄相关性听力损失;ARHL)。它影响着几乎每三位 65 岁以上的人。耳蜗中的毛细胞在声音登记过程中起着重要作用。遗传突变、衰老和环境因素会造成损伤,导致听力损失。<b>方法和结果:</b>目前探索的研究方向包括药物治疗、基因治疗和干细胞治疗。迄今为止,在中重度听力损失患者中,尚未证明皮质类固醇给药途径对治疗效果有显著差异。已经开发了新的含有地塞米松的水凝胶制剂,以及脂质制剂、热敏聚合物和纳米颗粒,以在内耳结构中实现高药物浓度。抗氧化剂或改变顺铂等物质的毒性作用的物质的耳保护作用也在研究中。听觉细胞再生的尝试在听力损失研究中似乎很有前途。为此,正在探索调节 Notch 和 Wnt 通路中枢机制的物质。老年性聋的遗传决定因素表明,针对特定基因的干扰可能是治疗这种疾病的一种有前途的选择。利用 CRISPR/Cas9 技术,可以通过破坏正常基因等位基因来有效研究内耳基因的功能。开发用于靶向特定基因的 CRISPR/Cas9 复合物,使用阳离子脂质、蛋白质和病毒载体进行递送。然后,它们通过扩散穿过圆窗膜,而无需对内耳进行手术破坏。用反义寡核苷酸治疗毛细胞变性引起的遗传性耳聋的潜力也已经确立。另一个研究方向与使用干细胞开发人类内耳的体外 3D 模型有关。还在进行研究以确定多能细胞来源的耳蜗类器官形成的机制,以及确定耳蜗感觉上皮发育和靶向毛细胞分化的关键时间点和事件。<b>结论:</b>总之,在过去十年中,人们在寻找治疗感觉性听力损失的新疗法方面取得了重大进展。这一研究领域仍然是一个雄心勃勃且重要的探索领域。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验